| dc.description.abstract | The aim of this study was to determine the effects of long-acting analogue Octreotide (Sandostatin LAR) on the level of growth hormone and insulin-like growth hormone and tumor size and clinical symptoms in patients with Acromegaly (examining the current status in the northwest of the country).
Materials and Methods:
In a retrospective observational study along with follow up in the Division of Endocrinology, Department of Internal Medicine, Tabriz University of Medical Sciences, on patients with Acromegaly, the effects of long-acting analogue Octreotide (Sandostatin LAR) was examined on the level of growth hormone and insulin-like growth hormone and tumor size and clinical symptoms in patients with Acromegaly (examining the current status in the northwest of the country).
Results:
In this study, the use of Sandostatin-LAR in patients with Acromegaly leads to recovery; so that 72.5% of patients expressed recovery and 27.5 % of patients expressed relative recovery. There was a significant reduction in adenoma tumor size after treatment with Sandostatin LAR compared to the mean adenoma tumor size before treatment (P=0.004). The mean level of pre-treatment IGF-1 was 703.304±72.39, the mean level IGF-1 at 3 months after treatment was 423.95±228.94, the mean level IGF-1 at 6 months after treatment was 366.05±195.20 μgr/l, and the mean level IGF-1 at 12 months after treatment was 297.113±50.67. Mean GH level at before, 3 months, 6 months and 12 months after treatment with Sandostatin LAR were 31.71±3.03, 10.31±5.23, 7.28±3.11 and 6.77±4.38 μgr/l, respectively.
There was a significant reduction in the level of IGF-1 and GH at 3 months, 6 months and 12 months after treatment compared to its pre-treatment level among patients (P<0.001). | en_US |
